Table 5.

Association of serum vitamin D concentration with prostate cancer risk: SELECT non–African Americans

ModelVitamin D (nmol/L)N (case)N (cohort)HR95% CIP
Overall prostate cancer
 Model 1a<37.51091881.00
37.5–<501892901.080.79–1.480.640
50–<754928520.910.69–1.190.476
≥756911,0711.000.76–1.310.999
 Model 2a,b<37.5971541.00
37.5–<501692990.790.57–1.100.166
50–<755168810.810.61–1.080.152
≥756991,0670.900.68–1.200.462
 Model 3a,b,c<50.62794811.00
50.6–<64.22734800.960.77–1.200.729
64.2–<77.92994800.950.77–1.180.670
77.9–<94.02824800.970.78–1.210.794
≥94.03484801.180.96–1.460.125
 Model 4a,b,d<44.11822771.00
44.1–<58.22634620.830.64–1.070.147
58.2–<72.92875260.740.57–0.940.015
72.9–<90.73475640.870.68–1.110.254
≥90.74025720.980.77–1.250.881
Gleason 2–6 prostate cancer
 Model 1a<37.5611881.00
37.5–<501202901.210.83–1.770.313
50–<752778520.900.65–1.260.551
≥754241,0711.060.76–1.470.726
 Model 2a,b<37.5571541.00
37.5–<501012990.800.54–1.190.274
50–<753038810.810.57–1.140.230
≥754211,0670.890.64–1.260.520
 Model 3a,b,c<50.61674811.00
50.6–<64.21494800.890.68–1.160.394
64.2–<77.91864800.980.76–1.270.880
77.9–<94.01624800.900.69–1.170.446
≥94.02184801.200.94–1.540.151
 Model 4a,b,d<44.11072771.00
44.1–<58.21574620.840.63–1.140.271
58.2–<72.91705260.730.55–0.990.039
72.9–<90.72035640.840.63–1.130.257
≥90.72455720.980.74–1.300.902
Gleason 7–10 prostate cancer
 Model 1a<37.5381881.00
37.5–<50492900.810.50–1.310.386
50–<751388520.740.49–1.110.143
≥751991,0710.860.58–1.280.456
 Model 2a,b<37.5301541.00
37.5–<50482990.740.44–1.240.254
50–<751448810.730.47–1.140.164
≥752021,0670.880.57–1.360.555
 Model 3a,b,c<50.6804811.00
50.6–<64.2844800.990.71–1.390.962
64.2–<77.9764800.850.60–1.200.354
77.9–<94.0854801.060.76–1.490.726
≥94.0994801.200.87–1.680.270
 Model 4a,b,d<44.1592771.00
44.1–<58.2654620.630.42–0.930.020
58.2–<72.9835260.670.46–0.980.039
72.9–<90.71035640.810.56–1.170.259
≥90.71145720.900.63–1.280.556
  • aHRs adjusted for age (through matching) and family history of prostate cancer, BMI, baseline diabetes, and SELECT treatment arm (as covariates).

  • bVitamin D values adjusted for month of serum sample.

  • cQuintiles are calculated based on the distribution among non–African American cohort.

  • dQuintiles are calculated based on the distribution among the entire cohort.